Home / Services / Regenerative medicine / IV exosome therapy
IV exosome therapy at a glance: what exosomes are, how they differ from stem cells, what the research does and does not show, safety, and how I decide whether it is appropriate.
IV Exosome Therapy in Dubai: A Cell-Free Approach to Regenerative Signalling
For patients exploring regenerative medicine who want to understand the difference between living-cell therapies and extracellular-vesicle therapy.
The question I hear most often is: “What is an exosome, and is it the same as a stem cell?” It is not. Exosomes are not stem cells, and they are not living cells at all.
What are exosomes?
Exosomes are microscopic packages, known more formally as small extracellular vesicles, that cells release to communicate with each other. Each one is a tiny bubble of lipid membrane that carries proteins, lipids, microRNAs and other biologically active molecules from one cell to another.
Researchers often prefer the broader term extracellular vesicles (EVs), because it is difficult to prove exactly how a particular vesicle was formed.1 I use “exosome” on this page because it is the word patients know.
Exosomes and stem cells: what is the difference?
Stem cell therapy gives living cells. Part of the benefit proposed for mesenchymal stromal cells is thought to come from the signals they release while they are present, including extracellular vesicles. Exosome therapy gives the signalling vesicles themselves.
Because the signalling cargo is already contained within extracellular vesicles, exosome therapy does not depend on administered cells remaining viable and subsequently releasing those signals. I do not claim that this makes exosomes work faster or better: no clinical trial has compared the two head to head.
| IV exosome (EV) therapy | IV stem cell (MSC) therapy | |
|---|---|---|
| Living cells? | No | Yes |
| Can divide or engraft? | No | Living cells, so possible in principle; most IV MSCs do not persist for long |
| Main concept | Delivers signalling cargo carried in vesicles | Cells are thought to act partly through the signals they release |
| Typical contents | Vesicles carrying proteins, lipids, RNA and other signalling molecules | Viable cells |
| Evidence | Emerging, largely investigational | Established for a limited number of indications, investigational for many others |
| Standardised dosing? | Not yet universal | Depends on the cell product and the indication |
For the stem cell side of the comparison, see stem cell therapy in Dubai and regenerative medicine in Dubai.
What if I do not want living cells given through a drip?
This is one of the main reasons patients ask about exosomes. Because exosomes are cell-free, they cannot divide, engraft or differentiate. That removes some theoretical concerns that apply only to living-cell therapies. It does not make exosome therapy risk-free.
What is actually inside an exosome product?
There is no single universal exosome formula. What a vesicle carries depends on the cell it came from, the conditions that cell was grown in, and how the vesicles were isolated and purified. Two products that are both labelled “exosomes” can differ substantially. International guidance on extracellular vesicle research stresses characterisation and standardisation for this reason,1 and a review of registered clinical trials found that isolation and characterisation methods were often poorly reported.3
These are the questions I ask about any product:
- Which cells were the vesicles collected from, and how were donors screened?
- How were the vesicles isolated and purified?
- How were they characterised (particle concentration, size, markers)?
- Were sterility and endotoxin tests done, and can I see the batch documentation?
- How were they stored and transported?
- On what regulatory basis can this product be used?
In my practice, the IV preparations are fresh, not freeze-dried, and come from GMP-certified laboratories. GMP certification matters, but it is not enough on its own: I want the documentation for the specific product I am using.
Where is exosome research heading?
Researchers are studying extracellular-vesicle therapies in tissue repair and regeneration, inflammation and immune signalling, and the biology of ageing, among many other areas. A critical review of registered clinical trials found 471 EV-related trials covering more than 200 diseases. Most were diagnostic, and the therapeutic trials mostly used vesicles from mesenchymal stromal cells, most often for respiratory illness.3
This is an investigational field. IV exosome therapy is not an established treatment for any disease, and it has not been shown to extend lifespan, reverse ageing or improve athletic performance. On this page I describe what is being studied, not what is proven.
Who I discuss it with
I do not offer IV exosome therapy as a treatment for any single condition. I discuss it with patients who are interested in regenerative, signalling-based medicine, always alongside, never instead of, the standard care for their condition. These are the situations I most often discuss, and the honest position on each:
- Longevity and healthy ageing. The aim is to support health at your current age, not to add years. Ageing involves changes in inflammation, metabolic health and cell signalling, and extracellular vesicles are being studied in that biology. There is no clinical evidence that IV exosomes extend lifespan.
- Insulin resistance and metabolic strain. Nutrition, exercise, sleep and, where appropriate, medication remain first-line. Chronically high glucose and insulin resistance are associated with a low-grade inflammatory state,4 which is one reason I am interested in signalling-based therapy in these patients. That is a rationale, not proof that exosomes treat insulin resistance.
- Hypothyroidism. Thyroid hormone treatment continues. Research on exosomes and stem cells in thyroid autoimmunity is at the laboratory and animal stage, with no controlled patient trials. See the evidence on Hashimoto’s and Graves’ disease.
- Anaemia. Anaemia always needs its cause found first, for example iron, vitamin B12 or folate deficiency, thyroid disease or chronic inflammation, and it is treated according to that cause. Exosomes are not a treatment for anaemia. I mention it because low iron and thyroid problems are also common, treatable contributors to hair loss and fatigue, so I check them before any regenerative treatment.
- Hair loss that has not responded to standard treatment. I check the usual contributors first, such as iron stores, thyroid function and hormones. The evidence for exosomes in hair loss is early and limited, and when I use them it is as part of a scalp treatment programme. See hair treatment.
Fresh exosomes with microneedling, for scalp and face
Exosomes do not always have to be given through a drip. In my practice, fresh exosomes can also be applied with the Dermapen (microneedling), on the scalp for hair and on the face. This is a useful option for patients who are afraid of injections, men in particular.
In my experience, injection gives the better result, but microneedling can still give good results, and it is a reasonable choice when needles are the barrier. That is clinical observation, not trial evidence, and the same questions about the product, its source and its documentation apply. See hair loss treatment in Dubai and men’s hair loss treatment.
Cell-free does not mean risk-free
The safety data are encouraging but limited. A 2024 meta-analysis of 21 published reports found a pooled serious adverse event rate of 0.7% (95% CI 0.1 to 5.2%) and a pooled adverse event rate of 4.4% (95% CI 0.7 to 22.2%).2 Those intervals are wide. The authors also pointed out that the studies differed widely in how the vesicles were manufactured, how they were dosed and how adverse events were reported, and they called for standardised reporting.2
Safety also depends on the product: its source, donor screening, manufacturing standard, purification, sterility, endotoxin testing, particle dose, storage and handling. The word “exosome” on a vial does not tell you what is inside it.
On regulation: the US FDA states that there are currently no FDA-approved exosome products.5 In Dubai, the Dubai Health Authority issued Circular 41/2026 on 7 October 2026 on unauthorised medical products containing exosomes and/or PDRN.6 Wherever you are treated, ask the clinic which product it is using, who made it, and on what regulatory basis it is used.
What happens at a consultation
- I take your history, your medication and any treatment you are already having.
- I review recent blood tests, or ask for them where relevant, for example iron studies, thyroid function and HbA1c, and treat any underlying cause first.
- We go through the product I would use and its documentation.
- We decide together whether it is appropriate. Sometimes the answer is not to treat. I do not give IV exosomes during an active infection, during pregnancy or breastfeeding, or to anyone with a history of cancer.
I do not promise outcomes, and I do not follow a fixed number of sessions, because there is no trial-based course to follow. Related reading: psoriasis and eczema, multiple sclerosis and IV drip therapy.
We’ve Got You Covered!
Curious? Start Here
An intravenous infusion of exosomes, which are small extracellular vesicles that cells release to communicate with each other. Exosomes are not stem cells and they are not living cells.
No. Stem cells are living cells. Exosomes are cell-free vesicles, so they cannot divide, engraft or differentiate. That does not make them risk-free.
No clinical trial has shown that. The signalling cargo is already contained within the vesicles, but that is a biological explanation, not evidence of faster or better results.
No. IV exosome therapy is investigational and is not an established treatment for any disease. I do not use it instead of standard care.
Reported serious adverse event rates were low in a 2024 meta-analysis, but the studies were few and varied and the confidence intervals were wide. Safety also depends on the specific product: its source, manufacturing, purification, sterility testing, dose, storage and handling.
The US FDA states that there are currently no FDA-approved exosome products. In the UAE, ask any clinic which product it uses, who made it, and on what regulatory basis it is used.
Yes, but that is a different route. In my practice, fresh exosomes can also be applied to the scalp or face with microneedling (Dermapen), which some patients prefer, men especially, if they are afraid of injections. The route, the product and the evidence differ from the intravenous route, and this page is about intravenous use.
Which product is it, who made it, how were the vesicles isolated and characterised, were sterility and endotoxin tests done, can I see the batch documentation, and on what regulatory basis is it used?
About the Author
Dr Shiva Faramarzi, MD
Aesthetic & Longevity Physician
Apogée Clinic, Address Beach Resort, JBR, Dubai
DHA Licence No. 43705219
Dr Shiva Faramarzi’s clinical interests include regenerative medicine, ultrasound-guided aesthetic procedures and the diagnosis and management of injectable complications.
Last updated: 20 October 2026
This page is provided for medical education and does not constitute individual medical advice. The suitability, regulatory status, risks and expected outcomes of any exosome or cell-based therapy depend on the specific product, indication and patient.
References
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. doi:10.1002/jev2.12404
- Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024;13(7):e12458. doi:10.1002/jev2.12458
- Mizenko RR, Feaver M, Bozkurt BT, et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024;13(10):e12510. doi:10.1002/jev2.12510
- Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. doi:10.1038/nature05485
- US Food and Drug Administration. Consumer alert on regenerative medicine products including stem cells and exosomes. Issued 22 July 2020; page current as of 9 April 2024. fda.gov
- Dubai Health Authority. Circular No. 41/2026: Regulatory instructions on the handling of unauthorized medical products containing exosomes and/or polydeoxyribonucleotide (PDRN). 7 October 2026. Ref. CIR-2026-00000177
IV Exosome Consultation
Discuss your goals, medical history and whether IV exosome therapy is appropriate for you. The product, its laboratory documentation and its regulatory status are reviewed before proceeding.
